Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory Diseases

  • Valero Martínez, Cristina|||0000-0003-2013-1545
  • Pardines-Ortiz, Marisa
  • Montes, Nuria
  • Dauden, Esteban|||0000-0002-0676-1260
  • Fernández-Gutiérrez, B.|||0000-0002-6126-8786
  • García-Planella, Esther|||0000-0002-4325-0697
  • Gomollón, Fernando|||0000-0003-0076-3529
  • Gratacós, Jordi|||0000-0003-4007-4103
  • Marsal, Sara|||0000-0001-5515-3854
  • Lamana, Amalia|||0000-0001-8779-5034
  • García-Vicuña, Rosario
  • González-Alvaro, Isidoro
  • Triguero-Martínez, Ana|||0000-0003-1580-2893
  • Pérez-Venegas, José J.
  • Julià Cano, Antonio|||0000-0001-6064-3620
Galectin-1 and -9 (Gal1/9) are essential mediators of immune-inflammatory responses, which makes these proteins potential biomarkers for immune-mediated diseases (IMIDs), such as rheumatoid arthritis (RA), psoriasis (PS), psoriatic arthritis (PsA), inflammatory bowel disease, and systemic lupus erythematosus (SLE). Our aim was to evaluate plasma Gal1/9 differences between IMID patients and healthy donors (HD). We analyzed 980 plasma samples divided into two analytical cohorts (600 discovery group and 380 validation group). Generalized linear models estimated Gal1/9 levels, adjusting for sex, age, storage time, and plate variability. In the overall IMID group, plasma Gal1 levels were comparable to those of HD, while Gal9 levels were significantly elevated. Levels varied across individual diseases: SLE patients consistently showed the highest Gal1/9 levels compared to both HD and other IMIDs, and RA patients had elevated Gal9 levels versus HD. Both Gal1 and Gal9 plasma levels correlated positively with higher disease activity, and Gal1 was higher in patients with longer disease duration. After adjustment for these confounders, SLE and RA patients maintained the highest Gal9 levels compared to HD. Our study demonstrates that Gal1 and Gal9 are differentially expressed across IMIDs, with particularly elevated levels in SLE, and both galectins are associated with disease activity.
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Publicación Artículo científico (JournalArticle)

Galectin-1 levels do not predict outcomes in undifferentiated arthritis: a two-year prospective observational study

  • Valero Martínez, Cristina
  • Pardines Ortiz, Marisa
  • Montes, Nuria
  • Ortiz, Ana María
  • García de Vicuña, Rosario
  • González Álvaro, Isidoro
  • Triguero Martínez, Ana
El articulo reporta los resultados negativos sobre la utilidad de los niveles séricos de Galectina 1 para predecir la evolución diagnóstica de pacientes con artritis indiferenciada en su primer contacto con el Sistema Nacional de Salud, INTRODUCTION: Undifferentiated arthritis (UA) represents an early and heterogeneous phase of inflammatory joint disease that may evolve into defined rheumatic conditions. This phase is characterized by immune dysregulation with loss of tolerance and early autoantibody production. Despite extensive research, reliable biomarkers for early diagnosis and prognosis remain lacking. Galectin-1 (Gal-1), an immunomodulatory lectin with anti-inflammatory properties, has been reported to be elevated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This study aimed to evaluate the diagnostic and prognostic value of serum Gal-1 levels in UA patients over a two-year follow-up. METHODS: This study analyzed patients from the observational PEARL study, that were classified as UA at baseline visit. After four standardized visits (0, 6, 12 and 24 months), in which biological samples, clinical, laboratory, and treatment data were systematically collected, a definitive diagnosis was established. Serum Gal-1 levels were measured by ELISA at all visits and analyzed in relation to clinical characteristics, final diagnosis, disease activity, and treatment intensity. Multivariate regression models were adjusted for relevant confounders. RESULTS: A total of 139 patients were included. After two years, 44.6% (n=62/139) progressed to a chronic inflammatory rheumatic disease, mostly RA (67%; n=42/62), while 40.2% (n=56/139) remained as persistent UA. Baseline Gal-1 levels were not associated with seropositivity, functional disability or treatment intensity. A non-significant trend toward lower Gal-1 levels was observed in patients evolving to spondyloarthritis (SpA) whereas no major differences were observed among other diagnostic groups. Over the two-year follow-up, Gal-1 levels remained largely stable across all diseases and did not correlate with disease activity despite significant clinical improvement. CONCLUSION: Overall, Gal-1 showed stable serum levels irrespective of disease activity or outcome, with limited predictive or monitoring value in UA. Lower concentrations observed in SpA suggest disease-specific modulation.